Bausch Health Cos (NYSE:BHC) Stock Price Target Raised at Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised Bausch Health’s price target from $9 to $10 while maintaining a “sector perform” rating, implying 10.72% upside from the prior close. The broader analyst consensus remains “Hold,” with an average target of $8.33.
• Bausch Health reported quarterly adjusted EPS of $1.77, beating the $1.25 consensus estimate, while revenue of $2.90 billion also exceeded expectations.
• The stock traded at $9.03 after rising $2.11, but the company continues to face financial challenges, including a negative net margin and highly negative return on equity.

Bausch Health Cos (NYSE:BHC - Get Free Report) had its price objective increased by investment analysts at Royal Bank Of Canada from $9.00 to $10.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a "sector perform" rating on the stock. Royal Bank Of Canada's price objective points to a potential upside of 10.72% from the company's previous close.

A number of other research firms have also recently weighed in on BHC. Jefferies Financial Group raised shares of Bausch Health Cos to a "hold" rating in a report on Wednesday, July 22nd. Zacks Research upgraded shares of Bausch Health Cos from a "hold" rating to a "strong-buy" rating in a research report on Monday, September 21st. Weiss Ratings upgraded shares of Bausch Health Cos from a "sell (d-)" rating to a "sell (d)" rating in a research note on Friday, July 31st. Finally, Wall Street Zen upgraded Bausch Health Cos from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $8.33.

Bausch Health Cos Stock Performance

Shares of Bausch Health Cos stock traded up $2.11 on Thursday, reaching $9.03. 19,179,705 shares of the company were exchanged, compared to its average volume of 2,569,605. The firm has a market cap of $3.38 billion, a price-to-earnings ratio of -3.03 and a beta of 0.37. Bausch Health Cos has a 1-year low of $4.33 and a 1-year high of $8.95. The company's 50-day moving average is $6.17 and its two-hundred day moving average is $5.71.

Bausch Health Cos (NYSE:BHC - Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The company reported $1.77 EPS for the quarter, topping analysts' consensus estimates of $1.25 by $0.52. The firm had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.72 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. As a group, sell-side analysts forecast that Bausch Health Cos will post 4.35 earnings per share for the current year.

Insider Buying and Selling

In other Bausch Health Cos news, insider Aimee Lenar sold 36,827 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total value of $258,893.81. Following the completion of the sale, the insider owned 334,853 shares in the company, valued at $2,354,016.59. This represents a 9.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company's stock.

Hedge Funds Weigh In On Bausch Health Cos

Institutional investors and hedge funds have recently modified their holdings of the stock. State of Wyoming raised its stake in shares of Bausch Health Cos by 62.1% during the 3rd quarter. State of Wyoming now owns 79,031 shares of the company's stock worth $461,000 after purchasing an additional 30,273 shares in the last quarter. Lebenthal Global Advisors LLC increased its holdings in shares of Bausch Health Cos by 69.4% during the 3rd quarter. Lebenthal Global Advisors LLC now owns 123,613 shares of the company's stock valued at $721,000 after acquiring an additional 50,644 shares during the last quarter. Sanders Morris Harris LLC acquired a new stake in Bausch Health Cos in the 3rd quarter worth approximately $169,000. Roxbury Financial LLC bought a new stake in Bausch Health Cos during the third quarter worth approximately $28,000. Finally, Engineers Gate Manager LP grew its holdings in Bausch Health Cos by 149.6% during the second quarter. Engineers Gate Manager LP now owns 249,991 shares of the company's stock valued at $1,232,000 after purchasing an additional 149,820 shares during the last quarter. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Strong earnings and revenue beat: Third-quarter revenue reached $2.94 billion, up 10% year over year and above analyst estimates. Adjusted earnings per share were $1.77, compared with a $1.25 consensus estimate and $1.16 a year earlier. BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
• Positive Sentiment: Salix growth drove momentum: The Salix business, including Xifaxan, contributed to revenue growth, while consolidated adjusted EBITDA rose 32% to $1.305 billion. Bausch Health also reported its fourteenth consecutive quarter of year-over-year revenue and adjusted EBITDA growth. Bausch Health Announces Third Quarter 2026 Results, Raises Guidance
• Positive Sentiment: 2026 outlook raised: Management increased its full-year revenue, adjusted EBITDA and adjusted operating cash-flow guidance, reinforcing expectations for continued operating improvement. The company generated $581 million in operating cash flow and $539 million in adjusted cash flow during the quarter. Bausch Health Announces Third Quarter 2026 Results, Raises Guidance
• Positive Sentiment: Debt reduction and buyback support sentiment: Bausch Health Americas plans to redeem approximately $643 million of 8.5% senior notes due 2027 using cash on hand, which could reduce interest costs and refinancing risk. The company also authorized a $50 million share-repurchase program, primarily to offset employee-equity dilution. Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
• Neutral Sentiment: Options activity was unusually elevated, with investors purchasing 6,018 call options—more than double typical call volume—suggesting increased bullish speculation but not guaranteeing further gains.
• Negative Sentiment: The company continues to carry significant financial risk, including a history of negative net margin and highly negative return on equity. Redeeming debt with cash may improve leverage but reduces near-term liquidity.

About Bausch Health Cos

Bausch Health Companies Inc NYSE: BHC is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets.

The company markets products through businesses such as Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and its international pharmaceutical operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.